MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$34,890K
Free Cash flow
-$17,553K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from offering of common...
Proceeds from maturities of avai...
Interest income, net
Others
Negative Cash Flow Breakdown
Purchases of available-for-sale ...
Employee compensation (excluding...
Chronic cough in ipf clinical tr...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Chronic cough in ipf clinical trial expense
6,034
-
7,992
-
Refractory chronic cough clinical trial expense
3,106
-
1,457
-
Clinical trial material
3,904
-
1,827
-
Chronic cough in ipf clinical trial expense
-
-
-
822
Other clinical trials and studies
2,443
-
6,219
-
Refractory chronic cough clinical trial expense
-
-
-
119
Other clinical development expenses
3,371
-
5,942
-
Clinical trial material
-
-
-
5,058
Employee compensation (excluding stock compensation expense)
6,506
-
11,820
-
Other clinical trials and studies
-
-
-
27
Other clinical development expenses
-
-
-
1,548
Employee compensation (excluding stock compensation expense)
-
-
-
3,041
Stock-based compensation expense
5,463
-
1,350
3,835
Other segment items
4,554
-
2,335
6,518
Interest income, net
4,392
-
1,903
4,633
Net loss
-17,797
-13,192
-8,316
-11,802
Stock-based compensation
3,272
2,191
1,350
1,243
Operating lease right-of-use assets
102
105
107
108
Depreciation and amortization
34
34
31
38
Accretion of available-for-sale marketable securities, net
517
431
562
298
Write off of deferred offering costs
-
-
26
-
Accounts payable
-276
-1,483
123
-282
Loss on disposal of property, equipment and leasehold improvements
-
-
-7
-
Accrued expenses and other liabilities
685
-1,075
-555
143
Prepaid expenses and other current assets
2,932
2,838
-158
30
Net cash used in operating activities
-17,429
-16,689
-7,631
-10,880
Proceeds from maturities of available-for-sale marketable securities
41,650
25,552
23,788
20,684
Purchases of available-for-sale marketable securities
153,564
8,485
54,396
71,610
Purchases of property, equipment and leasehold improvements
124
102
0
12
Net cash used in investing activities
-112,038
16,965
-30,608
-50,938
Proceeds from offering of common stock, net of commissions
54,861
-
-
0
Proceeds from offering, net of commissions
-
-
108,154
-
Proceeds from exercises of warrants
-
-
0
0
Proceeds from exercises of stock options
1,721
222
225
1,123
Proceeds from disgorgement of beneficial owner's short-swing profits
-
-
0
725
Proceeds from employee stock purchase plan
66
-
59
0
Payments of offering costs
445
-
0
219
Payments of finance lease
-
-
0
0
Proceeds from at-the-market sales agreement, net of commissions and allocated fees
-
-
-
0
Net cash provided by financing activities
164,357
222
284
1,629
Net increase in cash and cash equivalents
34,890
498
-37,955
-60,189
Cash and cash equivalents at beginning of period
19,412
18,914
56,869
34,097
Cash and cash equivalents at end of period
54,302
19,412
18,914
56,869
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
something is missing
$108,154K
Proceeds from offering of
common stock, net of...
$54,861K
(-49.28%↓ Y/Y)
Proceeds from exercises
of stock options
$1,721K
(135.43%↑ Y/Y)
Proceeds from employee
stock purchase plan
$66K
(11.86%↑ Y/Y)
Net cash provided by
financing activities
$164,357K
(38.00%↑ Y/Y)
Canceled cashflow
$445K
Net increase in cash
and cash...
$34,890K
(-57.94%↓ Y/Y)
Canceled cashflow
$129,467K
Payments of offering
costs
$445K
(-24.58%↓ Y/Y)
Proceeds from maturities
of...
$41,650K
(29.77%↑ Y/Y)
Stock-based compensation
$3,272K
(26.23%↑ Y/Y)
Accrued expenses and
other liabilities
$685K
(168.30%↑ Y/Y)
Operating lease
right-of-use assets
$102K
(-54.05%↓ Y/Y)
Depreciation and
amortization
$34K
(-54.67%↓ Y/Y)
Net cash used in
investing activities
-$112,038K
(-791.95%↓ Y/Y)
Net cash used in
operating activities
-$17,429K
(26.08%↑ Y/Y)
Canceled cashflow
$41,650K
Canceled cashflow
$4,093K
something is missing
$13,192K
Interest income, net
$4,392K
(73.46%↑ Y/Y)
Purchases of
available-for-sale marketable...
$153,564K
(243.88%↑ Y/Y)
Net loss
-$17,797K
(21.39%↑ Y/Y)
Purchases of property,
equipment and leasehold...
$124K
Canceled cashflow
$17,584K
Prepaid expenses and
other current assets
$2,932K
(82.57%↑ Y/Y)
Accretion of
available-for-sale marketable...
$517K
(-33.55%↓ Y/Y)
Accounts payable
-$276K
(37.13%↑ Y/Y)
Employee compensation
(excluding stock...
$6,506K
(12.66%↑ Y/Y)
Chronic cough in ipf
clinical trial expense
$6,034K
(1.91%↑ Y/Y)
Stock-based compensation
expense
$5,463K
(110.76%↑ Y/Y)
Other segment items
$4,554K
(1.81%↑ Y/Y)
Clinical trial material
$3,904K
(592.20%↑ Y/Y)
Other clinical
development expenses
$3,371K
(2.81%↑ Y/Y)
Refractory chronic cough
clinical trial expense
$3,106K
(148.08%↑ Y/Y)
Other clinical trials
and studies
$2,443K
(85.50%↑ Y/Y)
Buy us a coffee
Trevi Therapeutics, Inc. (TRVI)
Trevi Therapeutics, Inc. (TRVI)